EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC
Journal: Archive of Organ Transplantation (Vol.1, No. 3)Publication Date: 2015-12-17
Authors : Fabio Villa;
Page : 078-079
Keywords : Non-small cell lung cancer; EGFR; Adjuvant; Neoadjuvant; Thoracic surgery;
Abstract
5-year survival rates of Non-Small Cell Lung Cancer (NSCLC) remain unsatisfactory after surgery with curative intent and disease recurrences, including distant metastases, are frequent. Only a minority of this heterogeneous disease is positive for EGFR mutations and suitable for Tyrosine Kinase-Inhibitor biological agents, which however present limits in terms of stable response to treatment, due to the acquired drug resistances. A few trials administrating EGFR inhibitors combined with surgery, in neoadjuvant or adjuvant settings, have been reported with lack of evidence. The third-generation EGFR inhibitors, with the amelioration of techniques of gene profiling and the knowledge of pathways could extent the spectrum of complementary-to-surgery treatments in NSCLC at high risk of relapse.
Other Latest Articles
- Integrating the Green City Concept in Retooling the City in Africa - A Neo-Mercantile Planning and Plant Science Partnership
- Takayasu Arteritis in a Female- A Rare Case Report from Rural India
- Complications of Hydatid Cysts in the Lung
- Estimation of the Wild Boar Population in the Italian Apennines by Pellet Count Group Technic- A Pilot Study
- Fitness, Lifestyle Changes, and Wellness: Cardiometabolic Health
Last modified: 2019-03-30 19:19:13